U.S. Centers For Medicare & Medicaid Services Has Assigned A Permanent And Product-specific J-code For Krystal Biotech's Vyjuvek For Dystrophic Epidermolysis Bullosa, Effective January 1, 2024
Portfolio Pulse from Benzinga Newsdesk
The U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code for Krystal Biotech's Vyjuvek, a treatment for Dystrophic Epidermolysis Bullosa, which will be effective from January 1, 2024. This J-code facilitates billing and reimbursement processes for Vyjuvek, potentially improving its market accessibility and adoption.
January 04, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech's Vyjuvek has been assigned a permanent J-code by CMS, effective January 1, 2024, which is expected to streamline the reimbursement process and potentially boost sales.
The assignment of a permanent J-code is a significant regulatory milestone for Krystal Biotech, as it simplifies the reimbursement process for Vyjuvek, making it more accessible to patients and healthcare providers. This is likely to have a positive impact on the adoption and sales of the product, which could, in turn, lead to an increase in the company's revenues. The positive impact is anticipated to be more pronounced as the effective date approaches and once the code is in use.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100